SaaS AI Platform for Trial Optimization 1454

Our client has built a revolutionary Predictive Digital Twin platform transforming the clinical trial industry through AI-driven prognostic modeling. Founded by a Harvard-trained physician-scientist and robotics engineer, our client addresses the multibillion-dollar problem of patient recruitment and retention failures in pharmaceutical trials. Using Federated Learning and a proprietary Self-Correcting Transformer (SCT) engine, our client integrates real-time clinical, molecular, and biosensor data to predict Enrollment Quality, Adherence Probability, and Therapeutic Response for each participant. This ensures the right patient is matched with the right trial — accelerating development timelines and reducing costs for sponsors. NDA required to receive comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Detailed Information Facilities: Home based business, portable. Competition: None have this revolutionary technology. Growth & Expansion: The company employs a Hybrid SaaS revenue model with recurring clinical site subscriptions and enterprise success fees from large pharmaceutical partners. The company is on the cusp of rapid growth but cannot do so on its own balance sheet presently to service customers already wanting to do business with the Company###-###-#### will be $.3M, year 3 is projected to be > $10M, year 5 is projected to be > $50M in revenue. With secured clinical partnerships and technical collaborations with AI and data science experts, our client is positioned for exponential scale in the $60B+ clinical research market. Financing: TBD if structure and terms are acceptable. Support & Training: As needed. Reason for Selling: Find a growth partner to finalize MVP commercialization and expand enterprise adoption.